68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Nov 27, 2022
Trial Information
Current as of January 22, 2025
Unknown status
Keywords
ClinConnect Summary
Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs; e.g., FAPI-04 and FAPI-46), which have shown promising results in the diagnosis of cancer and various other diseases in recent years, have become the focus of much productive research. Despite this, one major issue is that these FAPI molecules have a relatively short tumor retention time, which may limit their use in targeted radionuclide therapy applications. As a result, 68Ga-DOTA-F2, a novel dimeric FAPI molecule, was developed to increase tracer uptake and retention in tumors for potential therapeutic or theranostic ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subject is aged 18 years or older
- • 2. Signed Informed Consent
- • 3. Subject is pathologically confirmed with a malignant tumor
- • 4. Subject is judged to be in good general condition by the investigator based on medical history, physical examination including vital signs and clinical laboratory tests, besides the diagnosis of malignant tumor
- • 5. Female subjects should be post-menopausal or surgically sterile or using effective contraceptive with the negative pregnancy test
- Exclusion Criteria:
- • 1. Subject has a previous or ongoing recurrent or chronic disease, other than malignant tumor, at high risk to interfere with the evaluation of the trial according to the judgment of the investigator
- • 2. Subject with non-malignant lesions;
- • 3. Subject with the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
- • 4. Subject is potentially pregnant (serum and urinary hCG test will be performed in women where pregnancy is not excluded) or is breast-feeding
Trial Officials
Fang Li, MD
Principal Investigator
Peking Union Medical College Hospital
About Peking Union Medical College Hospital
Peking Union Medical College Hospital (PUMCH) is a prestigious medical institution and a leading research facility located in Beijing, China. Affiliated with the Chinese Academy of Medical Sciences, PUMCH is renowned for its commitment to advancing healthcare through innovative clinical research and high-quality patient care. The hospital plays a pivotal role in the development and execution of clinical trials across various medical disciplines, focusing on improving treatment outcomes and enhancing medical knowledge. With a multidisciplinary team of experts and state-of-the-art facilities, PUMCH is dedicated to contributing to global health advancements and fostering collaborations in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials